Fate Therapeutic Stock Price, News & Analysis

Fate Therapeutics (NASDAQ: FATE) reported updated Phase 1 data for off-the-shelf CAR T product FT819 in 10 treatment-refractory moderate-to-severe systemic lupus erythematosus (SLE) patients as of a Sept 25, 2025 data cut.

Key findings: single-dose FT819 produced rapid CD19+ B-cell depletion, immune remodeling toward a naïve B-cell repertoire, durable clinical responses including two complete renal responses (CRR) at 6 months and one patient in steroid-free DORIS at 15 months, low-grade CRS only, no ICANS or GvHD, and potential for same-day discharge and outpatient administration.

Fate Therapeutics (NASDAQ: FATE) appointed Kamal Adawi as Chief Financial Officer effective October 20, 2025. Mr. Adawi brings more than 20 years of life‑sciences financial leadership, including over 10 years as CFO and experience leading Exagen through an IPO. The company will grant an inducement package: a 375,000 non‑qualified stock option exercisable at the closing price on October 20, 2025, vesting over four years, and 75,000 restricted stock units vesting in four annual tranches starting November 1, 2026. Grants are made under the Amended and Restated Inducement Equity Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Fate Therapeutics (NASDAQ: FATE) announced on October 1, 2025 inducement equity awards to one newly hired non-executive employee under its Amended and Restated Inducement Equity Plan pursuant to Nasdaq Listing Rule 5635(c)(4). The grants consist of 60,000 non-qualified stock options with an exercise price of $1.25 (closing price on grant date) and 45,800 restricted stock units (RSUs).

The options vest over four years (25% at one year, then monthly over 36 months); the RSUs vest 25% each anniversary over four years, both subject to continuous employment. Grants were approved by the Compensation Committee.

Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies, announced new employee equity inducement grants on September 2, 2025.

The company granted non-qualified stock options for 45,000 shares at $1.03 per share to one new non-executive employee. Additionally, restricted stock units (RSUs) for 63,000 shares were awarded to two non-executive employees. The options and RSUs will vest over four years, with initial 25% vesting after one year, followed by monthly or annual vesting schedules respectively.

Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on developing iPSC-derived off-the-shelf cellular immunotherapies, has announced its participation in two major investor conferences in September 2025.

The company will attend the 2025 Wells Fargo Healthcare Conference on September 3 in Boston for one-on-one meetings, and will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on September 4 at 10:55 AM ET in New York. Webcasts of the presentations, if recorded, will be available on the company's investor relations website.

Fate Therapeutics (NASDAQ: FATE) reported significant progress in its Q2 2025 financial results and clinical developments. The company's lead candidate FT819, an off-the-shelf CAR T-cell therapy, showed promising durability in treating lupus nephritis, achieving remission at 12-month follow-up. The FDA has granted RMAT designation for FT819, and discussions are underway for a potential registrational pathway.

Key financial metrics include $248.9 million in cash and investments, with an extended operational runway through 2027. Q2 revenue was $1.9 million, while operating expenses totaled $38.9 million. The company implemented cost-saving measures, including a 12% workforce reduction.

Notable pipeline developments include FDA IND allowance for FT836 targeting solid tumors, extension of the Ono Pharmaceuticals partnership, and advancement of the FT839 dual-CAR T-cell program.

Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies, has announced new employee inducement awards. The company granted stock options for 60,000 shares to one new non-executive employee at $1.06 per share, and restricted stock units (RSUs) for 60,800 shares to two new non-executive employees.

The awards, approved by the Compensation Committee and granted under the company's Amended and Restated Inducement Equity Plan, include a four-year vesting schedule. The stock options vest 25% after one year, with remaining 75% vesting monthly over 36 months, while RSUs vest 25% annually over four years.

Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies, has announced new employee inducement equity awards. The company granted stock options for 30,000 shares at $1.12 per share to one new non-executive employee and restricted stock units (RSUs) for 37,900 shares to two new non-executive employees.

The awards, approved by the Compensation Committee and granted under the company's Amended and Restated Inducement Equity Plan, include a 4-year vesting schedule. Stock options vest 25% after one year with remaining monthly installments over 36 months, while RSUs vest 25% annually over four years.

Fate Therapeutics announced promising clinical data for FT819, its off-the-shelf CAR T-cell therapy, in treating systemic lupus erythematosus (SLE). All three lupus nephritis patients treated with FT819 under a fludarabine-free conditioning regimen achieved Primary Efficacy Renal Response, with the first patient maintaining drug-free remission at 12 months. An extrarenal lupus patient showed disease improvement, while another patient treated without conditioning achieved and maintained Low Lupus Disease Activity State at 6 months. The therapy demonstrated favorable safety across 59 patients, with low-grade cytokine release syndrome, no neurotoxicity, and no graft-versus-host disease. The company plans to expand the program to other autoimmune conditions and has approximately 450 cryopreserved drug product bags available.